# US 2025/0082785 A1 · Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082785 A1
- Document ID: US20250082785A1
- Status: Published application
- Kind: A1
- Application number: 18/816,096
- Filed: 2024-08-27
- Published: 2025-03-13
- Earliest claimed: 2016-08-03
- Assignees: Washington University
- Applicants: Washington University
- Inventors: John F. DiPersio; Matthew Cooper
- Web page: https://patentgrep.com/patent/US20250082785A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4211: {CD19 or B4}
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0636: {T lymphocytes}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides the use of fratricide-resistant chimeric antigen receptor T (CAR-T) cells targeting antigens expressed by T cell malignancies.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A process for producing a population of anti-CD7-CAR (chimeric antigen receptor)-expressing human T cells by multiplexed editing, the process comprising:
(a) expressing in a population of activated human T cells a CRISPR/Cas editing system;
(b) contacting the population of activated human T cells of step (a) with at least two guide polynucleotides, each targeting a polynucleotide encoding a different protein of interest, wherein the proteins are CD7 and TRAC (T cell receptor alpha chain);
(c) modifying at least two gene sequences or regulatory elements thereof in the population of activated human T cells using a means for mutating, deleting, replacing or disrupting the genomic DNA encoding the protein of interest, resulting in reduction or elimination of the expression of CD7 and TRAC; and
(d) transducing the modified activated human T cells of step (c) with an anti-CD7 CAR.

### Claim 22 (depends on 21)

The process of claim 21, further comprising expanding the population of transduced T cells, thereby obtaining a population of CD7-deficient and TCR-deficient human T cells.

### Claim 23 (depends on 21)

The process of claim 21, wherein the population of anti-CD7-CAR-expressing human T cells has reduced risk of fratricide and/or reduced risk of Graft versus Host Disease (GVHD).

### Claim 24 (depends on 23)

The process of claim 23, wherein the cell surface expression of CD7 is reduced by at least about 90% in the resultant population when compared to a control cell population without the modification.

### Claim 25 (depends on 24)

The process of claim 24, wherein endogenous T cell receptor mediated signaling is blocked in the CAR-T cell.

### Claim 26 (depends on 21)

The process of claim 21, wherein the guide polynucleotide targeting CD7 comprises
(a) an RNA sequence comprising residues 1-20 of SEQ ID NO: 17;
(b) an RNA sequence comprising residues 1-20 of SEQ ID NO: 18;
(c) an RNA sequence comprising residues 1-20 of SEQ ID NO:10;
(d) an RNA sequence comprising residues 1-20 of SEQ ID NO: 16; or
(e) an RNA sequence comprising residues 1-20 of any one of the sequences set forth in 16SEQ ID NO: 7-9 or 11-15.

### Claim 27 (depends on 26)

The process of claim 26, wherein the guide polynucleotide targeting TRAC comprises the RNA sequence of SEQ ID NO: 19.

### Claim 28 (depends on 27)

The process of claim 27, wherein the Cas protein is delivered into the cell as a nucleic acid encoding the Cas protein.

### Claim 29 (depends on 28)

The process of claim 28, wherein the nucleic acid encoding the Cas protein is mRNA.

### Claim 30 (depends on 29)

The process of claim 29, wherein the Cas protein is delivered into the cell in protein form.

### Claim 31 (depends on 30)

The process of claim 30, wherein the gRNAs targeting the genes to be edited are delivered contemporaneously with the Cas protein.

### Claim 32 (depends on 31)

The process of claim 31, wherein the delivery is by electroporation.

### Claim 33 (depends on 32)

The process of claim 32, wherein the Cas protein is Cas9.

### Claim 34 (depends on 28)

The process of claim 28, wherein the transducing of the modified activated human T cells is effected by delivery of a lentiviral vector encoding the CAR.

### Claim 35 (depends on 34)

The process of claim 34, wherein the CAR comprises a 4-1BB costimulatory domain.

### Claim 36 (depends on 34)

The process of claim 34, wherein the CAR comprises a CD28 costimulatory domain.

### Claim 37 (depends on 34)

The process of claim 34, wherein the CAR comprises a signaling domain comprising a CD3ζ effector domain.

### Claim 38 (depends on 21)

The process of claim 21, wherein the T cells are primary T cells obtained from a donor who does not have a T cell malignancy.

### Claim 39 (depends on 38)

The process of claim 38, wherein the T cell malignancy is T cell acute lymphoblastic leukemia (T-ALL).

### Claim 40

A high efficiency process for producing a population of clinical-grade anti-CD7 CAR-expressing human T cells by multiplexed editing, the process comprising:
(a) expressing in a population of inactivated human T cells derived from a healthy human donor, a CRISPR/Cas editing system;
(b) contacting the population of human T cells of step (a) with at least two guide polynucleotides, each targeting a polynucleotide encoding a different protein of interest, wherein a first guide polynucleotide targets CD7 and comprises an RNA sequence comprising residues 1-20 of SEQ ID NO: 17 or residues 1-20 of SEQ ID NO: 18, or an RNA sequence comprising residues 1-20 of SEQ ID NO: 10 or residues 1-20 of SEQ ID NO: 16, and a second guide polynucleotide targets TRAC and comprises the RNA sequence of SEQ ID NO: 19;
(c) modifying the genomic DNA in the population of human T cells of step (b) using a means for mutating, deleting, replacing or disrupting the genomic DNA encoding the protein of interest, resulting in reduction or elimination of the cell surface expression of CD7 by at least about 97% in the resultant population when compared to a control cell population without the modifications;
(d) transducing the activated cells of step (c) with an anti-CD7 CAR; and
(e) expanding the cells of step (d), to create a population of anti-CD7 CAR-expressing human T cells having reduced risk of fratricide and reduced risk of graft versus host disease (GVHD).

### Claim 41

(canceled)

### Claim 42

A high efficiency means for modifying the genomic DNA in a population of human T cells that reduces the cell surface expression of CD7 and TRAC by at least about 70% in the resultant cell population when compared to a control cell population without the modifications.

### Claim 43 (depends on 21)

A method of treating a human subject having a T cell malignancy, the method comprising, administering the population of anti-CD7-CAR-expressing human T cells obtained from the process of claim 21 to the human subject.

### Claim 44 (depends on 21)

A population of genome-edited human T cells, comprising the population of anti-CD7-CAR-expressing human T cells obtained from the process of claim 21.

### Claim 45

A method of preparing cells for immunotherapy comprising:
(a) modifying T cells by reducing or eliminating expression of CD7 comprising introducing into said T cells a gRNA molecule comprising an RNA sequence comprising residues 1-20 of SEQ ID NO: 17 or residues 1-20 of SEQ ID NO: 18;
(b) modifying the T cells by reducing or eliminating expression of TRAC comprising introducing into said T cells a gRNA molecule comprising the RNA sequence of SEQ ID NO: 19; and
(c) expanding said cells.

### Claim 46 (depends on 45)

The method of claim 45, wherein said modifying takes place before the step of expanding said cells.

### Claim 47 (depends on 46)

The method of claim 46, further comprising transducing the T cells with a lentiviral vector comprising a nucleic acid encoding a chimeric antigen receptor (CAR).

### Claim 48 (depends on 47)

The method of claim 47, wherein the CAR comprises an antigen binding domain that specifically binds a CD7 antigen expressed on the surface of a malignant T cell.
